Blinatumomab improves outcomes in adult MRD-negative BCP-ALL

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-08-12 DOI:10.1038/s41571-024-00936-5

Diana Romero

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Blinatumomab可改善MRD阴性成人BCP-ALL的治疗效果

诱导化疗后最小残留病灶（MRD）阴性的成人B细胞前体急性淋巴细胞白血病（BCP-ALL）患者的预后优于MRD+患者，尽管许多患者最终会复发。现在，来自III期E1910试验的数据表明，在巩固化疗中加入CD19 × CD3双特异性T细胞捕获剂blinatumomab可改善这种情况下的总生存期（OS）。那些获得MRD完全应答（骨髓中白血病细胞为0.01%，488名患者中有224名）的患者被随机分配（1:1）接受使用或不使用blinatumomab的标准巩固化疗，然后两组患者都接受标准维持治疗。MRD-患者的OS是主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.